



## ESOCAP ANNOUNCES PUBLICATION OF “THE ESOCAP-SYSTEM – AN INNOVATIVE PLATFORM FOR DRUG TARGETING IN THE ESOPHAGUS”

*Basel, Switzerland, August 24, 2020*

**EsoCap has announced that scientists from the University of Greifswald published exciting data demonstrating that a novel drug delivery technology enables targeted and long-lasting local therapy of the esophagus for the first time (Krause et al., J Control Release 2020; 327:1-7).**

In contrast to tablets, capsules or viscous fluids, which are known for short esophageal transit times, the EsoCap system ensures a targeted and long-lasting drug delivery in the esophagus. The team at the University of Greifswald demonstrated the feasibility of their novel delivery concept, which is based on application of a mucosal adhesive foil, in 12 healthy volunteers and showed that the system is well accepted and adheres to the esophageal mucosa for at least 15 minutes.

“This finding fundamentally alters the therapeutic options in the field of esophageal diseases” said Prof. Werner Weitschies, head of the Biopharmaceutics group at the Center of Drug Absorption and Transport. “These results are ground-breaking and form the basis for a promising new approach to local drug therapies for patients with a wide range of esophageal diseases, who currently have no suitable treatment options.”

“I am greatly impressed by the demonstration of EsoCap technology’s functionality”, said Dr. Werner Tschollar, President of the Board of EsoCap. “The EsoCap technology has tremendous potential to offer new treatment options for diseases of the esophagus.”

### About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short contact time of drugs, of one to two seconds, from the mouth to the stomach.

EsoCap owns and develops a unique drug delivery platform allowing efficient topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit [www.esocapbiotech.com](http://www.esocapbiotech.com).

### Contact:

Isabelle Racamier, CEO

EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)